Business Context and Reporting Period
Company: Biodexa Pharmaceuticals Plc (BDRX)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Biodexa is a clinical-stage biopharmaceutical company focused on gastrointestinal cancers and Type 1 Diabetes. The company has shifted its strategy from drug delivery technologies to a portfolio of clinical-stage assets: eRapa (rapamycin formulation for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer), MTX240 (molecular glue for Gastrointestinal Stromal Tumors, licensed from Otsuka in Feb 2026), and tolimidone (Lyn kinase activator for Type 1 Diabetes). The company de-prioritized its MTX110 program and closed its Cardiff laboratory in 2025.
Key Financial Metrics
| Metric (£ in thousands) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 0 | 0 | 381 |
| Net Loss | (6,384) | (5,729) | (7,079) |
| Accumulated Deficit | (155,808) | (150,424) | (144,767) |
| Cash and Cash Equivalents | 8,534 | 1,669 | 5,971 |
| Operating Cash Flow | (5,591) | (12,261) | (6,826) |
| Financing Cash Flow | 13,039 | 8,557 | 10,226 |
| Total Equity | 11,405 | 8,322 | 4,678 |
Note: All figures are in British Pounds Sterling (£). Revenue was nil for 2025 and 2024.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 11% to £6.38 million in 2025 compared to £5.73 million in 2024, driven by higher administrative costs.
- Administrative Costs: Increased by 27% to £4.84 million (from £3.79 million), primarily due to foreign exchange movements (£0.44 million) and increased professional fees (£0.73 million) related to financing transactions and the Otsuka acquisition.
- R&D Costs: Decreased by 27% to £3.96 million (from £5.44 million). This reduction reflects lower spend on pre-clinical studies and manufacturing for MTX228 (tolimidone) and MTX110, partially offset by eRapa costs. Notably, 77% of eRapa costs were offset by CPRIT grant income in 2025 (vs. 43% in 2024).
- Finance Income: Significant non-cash gain of £2.30 million recognized in 2025 (vs. £3.22 million in 2024) related to the revaluation of equity-settled derivative financial liabilities (warrants) due to share price movements.
- Liquidity: Cash position improved significantly to £8.53 million from £1.67 million, driven by net proceeds of £13.75 million from equity offerings and the Equity Line of Credit (ELOC).
Guidance, Outlook, and Risks
Outlook and Guidance
- Cash Runway: Management forecasts that current cash resources and the undrawn portion of the ELOC will fund operations through the third quarter of 2026, assuming current development plans continue.
- Financing Needs: Additional financing will be required in Q3 2026. The company has a $35.0 million ELOC with C/M Capital Master Fund LP; $8.92 million has been drawn to date, with $26.08 million remaining undrawn as of December 31, 2025.
- Development Milestones:
- eRapa: Phase 3 trial in FAP is active with 37 patients enrolled as of March 2026. FDA Fast Track designation received.
- MTX240: Goal to manufacture clinical supplies and dose the first patient in a Phase 1b/2a study by year-end 2026.
- Tolimidone: Phase 2a dose confirmation study ongoing.
Material Risks and Contingencies
- Going Concern: The independent auditors (PKF Littlejohn LLP) included an emphasis of matter paragraph regarding a material uncertainty that may cast doubt on the company's ability to continue as a going concern due to recurring losses and the need for additional financing.
- Financing Uncertainty: There is no guarantee the ELOC will be fully utilized or that other financing will be available on acceptable terms. Failure to raise capital could force the company to delay or discontinue development programs.
- Regulatory and Clinical Risk: As a pre-revenue clinical-stage company, success depends on regulatory approvals and clinical trial outcomes. Failure in trials or inability to secure licensing partners could materially harm the business.
- Share Price Volatility: The company has a history of reverse stock splits and ratio changes to maintain NASDAQ listing compliance. Future sales under the ELOC could cause dilution and downward pressure on the share price.
Key Facts for Investor Verification
- Going Concern Status: Verify the company's ability to secure financing before Q3 2026 to avoid liquidation basis accounting.
- ELOC Utilization: Monitor the drawdown of the remaining $26.08 million ELOC and the terms of future equity sales, which may be dilutive.
- Grant Dependency: Assess the sustainability of the eRapa program, which relies heavily on CPRIT grant funding (77% of costs offset in 2025).
- MTX240 Integration: Verify the progress of the newly licensed MTX240 asset (licensed Feb 2026) and the associated upfront payments and milestone obligations to Otsuka.
- Derivative Liability: Note the significant non-cash finance income/expense volatility driven by warrant revaluations, which impacts reported net loss but not cash flow.